Mark Murray

Mark has been a CFO in the life science sector for over 30 years, working with senior executives and their boards. His eye care experience includes the successful exits of Optimedica and Oculeve. Mark spent over 20 years with Guidant Corporation, where he was part of the senior management team through its $1 billion IPO until its acquisition in 2006 for $27 billion (by Boston Scientific and Abbott Labs). He has helped raise over $1.6 billion in equity and over $500 million in debt for public and private companies. Mark is currently a partner at FLG Partners, LLC. He holds a B.S. in business administration (accounting) from San Francisco State University.